Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases

Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy does not provide a sufficient Lp(a) reduction. For PCSK9 inhibi...

Full description

Bibliographic Details
Main Authors:	Victoria A. Korneva, Tatjana Yurjevna Kuznetsova, Ulrich Julius
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Biomedicines
Subjects:	lipoprotein(a) proprotein convertase subtilisin/kexin type 9 inhibitors inclisiran lipoprotein apheresis inhibitors of apolipoprotein(a) synthesis cardiovascular risk
Online Access:	https://www.mdpi.com/2227-9059/9/9/1271

Similar Items

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
by: Niki Katsiki, et al.
Published: (2023-04-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Novel Therapeutic Approaches for the Management of Elevated Lipoprotein(a): From Traditional Agents to Future Treatment Options
by: György Paragh, et al.
Published: (2024-03-01)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
by: Maria Francesca Greco, et al.
Published: (2020-07-01)

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
by: Matthew T. Mefford, et al.
Published: (2019-11-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
by: Arrigo F.G. Cicero, et al.
Published: (2022-01-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
by: Michael J. Wilkinson, et al.
Published: (2024-03-01)

Familial Hypercholesterolemia
by: FENG Siqin, et al.
Published: (2023-01-01)

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study
by: Runzhen Chen, et al.
Published: (2022-10-01)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
by: Coen van Solingen, et al.
Published: (2021-07-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
by: V.A. Serhiyenko, et al.
Published: (2023-03-01)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Payal Kohli, et al.
Published: (2016-05-01)

Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
by: Shamanna S Iyengar
Published: (2016-01-01)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
by: Jennifer A. Rymer, et al.
Published: (2020-05-01)

Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization
by: Anna Papanikolaou, et al.
Published: (2024-01-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
by: Safi U. Khan, et al.
Published: (2019-04-01)

Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008–2019
by: Levintow SN, et al.
Published: (2022-06-01)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
by: Bowen Lou, et al.
Published: (2022-10-01)

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
by: Ilaria Guella, et al.
Published: (2010-11-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

Novel Low-Density Lipoprotein Cholesterol Reduction Therapies for the Secondary Prevention of Cardiovascular Disease
by: Xing Wang, et al.
Published: (2023-10-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

Treatment of Hyperlipidemia: Consensus and Controversies
by: Christoph H Saely, et al.
Published: (2017-01-01)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
by: Toshiyuki Nishikido
Published: (2023-01-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund
by: Beata Bobrowska, et al.
Published: (2022-08-01)

PCSK9 inhibitors in clinical practice: Novel directions and new experiences
by: Loukianos S. Rallidis, et al.
Published: (2020-07-01)

Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
by: Terrence L Trentman, et al.
Published: (2016-01-01)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
by: Antonio J. Vallejo‐Vaz, et al.
Published: (2018-09-01)